K
Krishnansu S. Tewari
Researcher at University of California, Irvine
Publications - 318
Citations - 10954
Krishnansu S. Tewari is an academic researcher from University of California, Irvine. The author has contributed to research in topics: Cervical cancer & Bevacizumab. The author has an hindex of 47, co-authored 285 publications receiving 8202 citations. Previous affiliations of Krishnansu S. Tewari include University of Maryland Medical System & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Krishnansu S. Tewari,Michael W. Sill,Harry J. Long,Richard T. Penson,Helen Huang,Lois M. Ramondetta,Lisa M. Landrum,Ana Oaknin,Thomas J. Reid,Mario M. Leitao,Helen Michael,Bradley J. Monk +11 more
TL;DR: The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival.
Journal ArticleDOI
Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity
J. E. Epstein,Krishnansu S. Tewari,Kirsten E. Lyke,B. K. L. Sim,Peter F. Billingsley,Matthew B. Laurens,Matthew B. Laurens,Anusha Gunasekera,Sumana Chakravarty,Eric R. James,Martha Sedegah,Adam Richman,Soundarapandian Velmurugan,Sharina Reyes,Ming Lin Li,Kathryn Tucker,Adriana Ahumada,Adam Ruben,Tao Li,Richard E. Stafford,Abraham G. Eappen,Cindy Tamminga,Jason W. Bennett,Christian F. Ockenhouse,Jittawadee Murphy,Jack Komisar,N. Thomas,Mark Loyevsky,Ashley J. Birkett,Christopher V. Plowe,Christopher V. Plowe,Christian Loucq,Robert R. Edelman,Thomas L. Richie,Robert A. Seder,Stephen L. Hoffman +35 more
TL;DR: The results suggest that intravenous administration of this vaccine will lead to the prevention of infection with Plasmodium falciparum malaria and suboptimally immunogenic and protective.
Journal ArticleDOI
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman,Mark F. Brady,Thomas J. Herzog,Paul Sabbatini,Deborah K. Armstrong,Joan L. Walker,Byoung-Gie Kim,Keiichi Fujiwara,Krishnansu S. Tewari,David M. O'Malley,Susan A. Davidson,Stephen C. Rubin,Paul DiSilvestro,Karen Basen-Engquist,Helen Q. Huang,John K. Chan,Nick M. Spirtos,Raheela Ashfaq,Robert S. Mannel +18 more
TL;DR: The roles of secondary surgical cytoreduction and bevacizumab in this population of women with ovarian cancer with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy were explored.
Journal ArticleDOI
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Krishnansu S. Tewari,Michael W. Sill,Richard T. Penson,Helen Huang,Lois M. Ramondetta,Lisa M. Landrum,Ana Oaknin,Thomas J. Reid,Thomas J. Reid,Mario M. Leitao,Helen Michael,Philip J. DiSaia,Larry J. Copeland,William T. Creasman,Frederick B. Stehman,Mark F. Brady,Robert A. Burger,J. Tate Thigpen,Michael J. Birrer,Steven E Waggoner,David H. Moore,Katherine Y. Look,Wui Jin Koh,Bradley J. Monk +23 more
TL;DR: In this article, the authors report the prespecified final analysis of the primary objectives, OS and adverse events, assessed at the second interim and final analysis by the masked Data and Safety Monitoring Board.
Journal ArticleDOI
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
Daniela Matei,Virginia L. Filiaci,Marcus E. Randall,David G. Mutch,Margaret M. Steinhoff,Paul DiSilvestro,Katherine M. Moxley,Yong M. Kim,Matthew A. Powell,David M. O'Malley,Nick M. Spirtos,William Small,Krishnansu S. Tewari,William E. Richards,John Nakayama,Ursula A. Matulonis,Helen Q. Huang,David Miller +17 more
TL;DR: Chemotherapy plus radiation was not associated with longer relapse-free survival than chemotherapy alone in patients with stage III or IVA endometrial carcinoma.